| Literature DB >> 32607633 |
Roberto Iezzi1,2, Iacopo Valente3, Alessandro Cina3, Alessandro Posa3, Andrea Contegiacomo3, Andrea Alexandre3, Francesco D'Argento3, Emilio Lozupone3, Michele Barone3, Francesca Giubbolini3, Luca Milonia3, Andrea Romi3, Anna Rita Scrofani3, Alessandro Pedicelli3, Riccardo Manfredi3,4, Cesare Colosimo3,4.
Abstract
OBJECTIVES: To retrospectively analyze interventional radiology (IR) activity changes in the COVID-19 era and to describe how to safely and effectively reorganize IR activity.Entities:
Keywords: Infections; Interventional radiology; Neoplasms; Safety; Virus diseases
Mesh:
Year: 2020 PMID: 32607633 PMCID: PMC7326392 DOI: 10.1007/s00330-020-07041-y
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Patients’ demographic, clinical, and procedural data
| Clinical and demographic data | Procedural data |
|---|---|
| Sex | Type of procedure (diagnostic or therapeutic) |
| Age | Urgency of procedure (elective or emergency) |
| Date and time of admission | Guidance (fluoroscopy, US, CT) |
Symptoms at the time of procedure (fever, respiratory symptoms) | Oncological setting (procedures in non-oncologic patients—for benign diseases, procedures in oncologic patients—not focused on the tumor, oncological treatments–procedures focused on the tumor) |
Symptoms during the last 15 days (fever, respiratory symptoms) | Treated body part (head, thorax, abdomen, bone, other) |
Past medical history (previous or ongoing malignancy) | Ward of provenance (emergency department, intensive care unit, general wards) |
Epidemiologic link (possible contact with COVID-19 subjects or coming from high-risk areas) | Delay between last diagnostic imaging and IR procedure (for emergency procedures) |
| Patient risk stratification* | Number of bedside US-guided procedures |
*Patients were stratified into low risk/negative (no symptoms or epidemiologic link), intermediate risk/suspect (presence of symptoms at the time of procedure or during the previous 15 days, or epidemiologic link), high risk/suspect (presence of symptoms and epidemiologic link), and positive (positive test for SARS-CoV-2)
Baseline demographics, clinical, and procedural characteristics
| Variables | Overall | Non-COVID era (2019) | COVID era (2020) | |
|---|---|---|---|---|
| Patients | 1226 | 676 (55.1%) | 550 (44.9%) | |
| Age (years) | 64.93 ± 15.14 | 64.87 ± 15.7 | 65.00 ± 14.39 | .87 |
| Women | 618 (50.4%) | 340 (50.3%) | 278 (50.5%) | .89 |
| Number of Procedures | 1496 | 825 (55.15%) | 671 (45.85%) | <.001 |
| Ward of provenance (per procedure) | .01 | |||
| Emergency department | 181 (12.10%) | 115 (13.94%) | 66 (9.84%) | |
| General ward | 1176 (78.61%) | 647 (78.42%) | 529 (78.84%) | |
| Outpatients | 111 (7.42%) | 52 (6.30%) | 59 (8.79%) | |
| Intensive care units | 28 (1.87%) | 11 (1.33%) | 17 (2.53%) | |
| Procedural guidance | .03 | |||
| Fluoroscopy | 703 (46.99%) | 367 (44.48%) | 336 (50.07%) | |
| US | 251 (16.78%) | 141 (17.09%) | 110 (16.39%) | |
| CT | 136 (9.09%) | 87 (10.55%) | 49 (7.30%) | |
| US + CT | 8 (0.53%) | 2 (.24%) | 6 (.89%) | |
| US + fluoroscopy | 398 (26.60%) | 228 (27.64%) | 170 (25.34%) | |
| Bedside procedures | 16 (1.07%) | 12 (1.45%) | 4 (.60%) | .13 |
| Type of procedure | .22 | |||
| Diagnostic | 248 (18.1%) | 128 (15.5%) | 120 (17.9%) | |
| Therapeutic | 1248 (83.42%) | 697 (84.48%) | 551 (82.12%) | |
| Body part | .01 | |||
| Head | 132 (8.82%) | 65 (7.88%) | 67 (9.99%) | |
| Chest | 123 (8.22%) | 81 (9.82%) | 42 (6.26%) | |
| Abdomen | 1007 (67.31%) | 549 (66.55%) | 458 (68.26%) | |
| Bone | 62 (4.14%) | 27 (3.27%) | 35 (5.22%) | |
| Others | 172 (11.50%) | 103 (12.48%) | 69 (10.28%) | |
| Urgency of procedure | .18 | |||
| Elective | 1019 (68.1%) | 550 (66.7%) | 469 (69.9%) | |
| Emergency | 477 (31.9%) | 275 (33.3%) | 202 (30.1%) | |
| Delay time-dependent procedures (min) | 90 (40–180) | 90 (40–330) | 95 (52.5–130.5) | .70 |
| Oncological setting | .35 | |||
| Procedures in non-oncologic patients | 586 (39.17%) | 334 (40.48%) | 248 (36.96%) | |
| Procedures in oncologic patients | 642 (42.91%) | 342 (41.45%) | 300 (44.71%) | |
| Oncologic treatments | 268 (17.91%) | 149 (18.06%) | 123 (18.33%) |
CT computed tomography, min minutes, US ultrasound
Baseline demographics and clinical and procedural characteristics for the procedure performed before the “lockdown period” (pre-LDP: Jan 30–Mar 10)
| Variables | Overall | Non-COVID era LDP | COVID era LDP | |
|---|---|---|---|---|
| Patients | 725 | 346 (47.73%) | 379 (52.27%) | |
| Age (years) | 64.93 ± 15.14 | 64.98 ± 15.82 | 65.04 ± 14.44 | .516 |
| Women | 474 (50.16%) | 225 (48.70%) | 249 (51.55%) | .381 |
| Number of procedures | 945 | 462 (48.89%) | 483 (51.11%) | |
| Ward of provenance (per procedure) | .040 | |||
| Emergency department | 107 (11.32%) | 60 (12.99%) | 47 (9.73%) | |
| General ward | 733 (77.57%) | 363 (78.57%) | 370 (76.60%) | |
| Outpatients | 83 (8.78%) | 30 (6.49%) | 53 (10.97%) | |
| Intensive care units | 22 (2.33%) | 9 (1.95%) | 13 (2.69%) | |
| Procedural guidance | .006 | |||
| Fluoroscopy | 447 (47.30%) | 200 (43.29%) | 247 (51.14%) | |
| US | 152 (16.08%) | 70 (15.15%) | 82 (16.98%) | |
| CT | 96 (10.16%) | 60 (12.99%) | 36 (7.45%) | |
| US + CT | 5 (0.53%) | 1 (0.22%) | 4 (0.83%) | |
| US + fluoroscopy | 245 (25.93%) | 131 (28.35%) | 114 (23.60%) | |
| Bedside procedures | 12 (1.27%) | 12 (2.60%) | 0 | <.001 |
| Type of procedure | .168 | |||
| Diagnostic | 153 (16.19%) | 67 (14.50%) | 86 (17.81%) | |
| Therapeutic | 792 (83.81%) | 395 (85.50%) | 397 (82.19%) | |
| Body part | .013 | |||
| Head | 86 (9.10%) | 34 (7.36%) | 52 (10.77%) | |
| Thorax | 78 (8.25%) | 50 (10.82%) | 28 (5.80%) | |
| Abdomen | 620 (65.61%) | 301 (65.15%) | 319 (66.05%) | |
| Bone | 49 (5.19%) | 19 (4.11%) | 30 (6.21%) | |
| Others | 112 (11.85%) | 58 (12.55%) | 54 (11.18%) | |
| Emergency procedures | .661 | |||
| Elective | 669 (70.79%) | 324 (70.13%) | 345 (71.43%) | |
| Emergency | 276 (29.21%) | 138 (29.87%) | 138 (28.57%) | |
| Delay time-dependent procedures (min) | 226 (70–463) | 246 (68–540) | 179 (80–360) | .291 |
| Oncologic classes | .799 | |||
| Procedures in non-oncologic patients | 372 (39.37%) | 177 (38.31%) | 195 (40.37%) | |
| Procedures in oncologic patients | 412 (43.60%) | 204 (44.16%) | 208 (43.06%) | |
| Oncologic treatments | 161 (17.04%) | 81 (17.53%) | 80 (16.56%) |
CT computed tomography, LDP lockdown period, min minutes, US ultrasound
Baseline demographics and clinical and procedural characteristics for the procedure performed during the “lockdown period”
| Variables | Overall | Non-COVID era LDP | COVID era LDP | |
|---|---|---|---|---|
| Patients | 501 | 330 (65.87%) | 171 (34.13%) | |
| Age (years) | 64.88 ± 14.30 | 64.73 ± 15.64 | 64.88 ± 14.30 | .91 |
| Women | 281 (51.00%) | 190 (52.34%) | 91 (48.40%) | .38 |
| Number of procedures | 551 | 363 (65.88%) | 188 (34.12%) | < .001 |
| Ward of provenance (per procedure) | .048 | |||
| Emergency department | 74 (13.43%) | 55 (15.15%) | 19 (10.11%) | |
| General ward | 443 (80.40%) | 284 (78.24%) | 159 (84.57%) | |
| Outpatients | 28 (5.08%) | 22 (6.06%) | 6 (3.19%) | |
| Intensive care units | 6 (1.09%) | 2 (0.55%) | 4 (2.13%) | |
| Procedural guidance | .49 | |||
| Fluoroscopy | 256 (46.46%) | 167 (46.01%) | 89 (47.34%) | |
| US | 99 (17.97%) | 71 (19.56%) | 28 (14.89%) | |
| CT | 40 (7.26%) | 27 (7.44%) | 13 (6.91%) | |
| US + CT | 3 (0.54%) | 1 (0.28%) | 2 (1.06%) | |
| US + fluoroscopy | 153 (27.77%) | 97 (26.72%) | 56 (29.79%) | |
| Bedside procedures | 4 (.73%) | 0 | 4 (2.13%) | .01 |
| Type of procedure | .706 | |||
| Diagnostic | 95 (17.24%) | 61 (16.80%) | 34 (18.09% | |
| Therapeutic | 456 (82.76%) | 302 (83.20%) | 154 (81.91%) | |
| Body part | .54 | |||
| Head | 46 (8.35%) | 31 (8.54%) | 15 (7.98%) | |
| Thorax | 45 (8.17%) | 31 (8.54%) | 14 (7.45%) | |
| Abdomen | 387 (70.24%) | 248 (68.32%) | 139 (73.94%) | |
| Bone | 13 (2.36%) | 8 (2.20%) | 5 (2.66%) | |
| Others | 60 (10.89%) | 45 (12.40%) | 15 (7.98%) | |
| Emergency procedures | .39 | |||
| Elective | 350 (63.52%) | 226 (62.26%) | 124 (65.96%) | |
| Emergency | 201 (36.48%) | 137 (37.74%) | 64 (34.04%) | |
| Delay time-dependent procedures (min) | 86.5(40–180) | 50 (40–180) | 100(55–180) | |
| Oncologic classes | .003 | |||
| Procedures in non-oncologic patients | 210 (38.11%) | 157 (43.25%) | 53 (28.19%) | |
| Procedures in oncologic patients | 230 (41.74%) | 138 (38.02%) | 92 (48.94%) | |
| Oncologic treatments | 111 (20.15%) | 68 (18.73%) | 43 (22.87%) |
CT computed tomography, LDP lockdown period, min minutes, US ultrasound
Types of procedures performed by period of time
| Procedure types | Non-COVID era | COVID era | Non-COVID LDP | COVID LDP |
|---|---|---|---|---|
| Hepatic oncological treatments (ablation/TACE/TARE) | 58 | 49 | 23 | 16 |
| Other ablations | 5 | 2 | 3 | 0 |
| Hepatic/pulmonary biopsy | 59 | 44 | 25 | 15 |
| Other biopsy | 31 | 31 | 18 | 13 |
| Traumatic/post-surgical embolization (bleeding) | 33 | 33 | 16 | 10 |
| Embolization for benign diseases (UFE/varicocele/uterine fibroid embol/bronchial) | 26 | 5 | 13 | 1 |
| Presurgical embolization (PVE/tumoral embolization) | 4 | 6 | 3 | 2 |
| Urological therapeutic procedures (nephrostomy/ureteral stenting) | 192 | 145 | 85 | 47 |
| Biliary therapeutic procedures (drainage/stent) | 70 | 64 | 25 | 18 |
| Cholecystostomy | 16 | 10 | 8 | 3 |
| Abdominal drainage | 130 | 104 | 55 | 28 |
| Thoracic drainage | 9 | 5 | 3 | 1 |
| Extracranial/peripheral AVM/DAVF embolization | 8 | 6 | 4 | 0 |
| Abdominal/peripheral revascularization | 88 | 53 | 39 | 9 |
| TIPS | 1 | 5 | 0 | 2 |
| Caval procedures (filter/foreign body removal) | 12 | 13 | 5 | 4 |
| Ischemic stroke | 18 | 29 | 9 | 12 |
| Cerebral aneurysm embolization | 24 | 16 | 11 | 0 |
| Spinal/vertebral procedures | 25 | 34 | 8 | 4 |
| Diagnostic cerebral angiography | 15 | 17 | 10 | 3 |
AVM artero-venous malformation, DAVF dural artero-venous fistulas, LDP “lockdown period” (between 11 March and 8 April), PVE portal vein embolization, TACE transcatheter arterial chemoembolization, TARE trans-arterial radioembolization, TIPS transjugular intrahepatic portosystemic shunt, UFE uterine fibroid embolization